A Safety, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects and Patients Diagnosed With Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 31 May 2013
At a glance
- Drugs LY 2886721 (Primary)
- Indications Alzheimer's disease
- Focus Biomarker; Pharmacodynamics; Pharmacokinetics
- 10 Jun 2017 Biomarkers information updated
- 31 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.